U.S. Pharma Stock News

QXO, Inc. recently announced that Chief Accounting Officer Sean Smith resigned effective March 15, 2026, and appointed veteran finance executive Robert Loughran as Interim Chief Accounting Officer the following day while it searches for a permanent successor. The decision to bring in an interim leader with extensive SEC reporting and internal controls experience underscores how seriously QXO is treating continuity in its financial oversight function. We’ll now examine how this change in the...

If you are wondering whether CleanSpark's current share price lines up with its underlying worth, this breakdown will help you connect the stock chart to valuation numbers. CleanSpark closed at US$9.40, with returns of 1.4% over the last 30 days, an 18.6% decline year to date, gains of 26.3% over 1 year, and a very large 3 year return of 249.4%, set against a 55.3% decline over 5 years. Recent coverage has focused on CleanSpark as part of broader commentary on software and tech related...

Darden Restaurants (DRI) just turned in its Q3 2026 scorecard, reporting revenue of US$3.3b and basic EPS of US$2.70. This helps investors weigh the latest quarter against its recent track record. Over the past few periods, revenue has moved from US$3.2b in Q3 2025 to US$3.3b in Q3 2026, while basic EPS went from US$2.76 to US$2.70, giving a clear sense of where the top and bottom lines currently sit. With net profit margin now at 8.7% versus 9.0% a year earlier, the story for this quarter...

Humacyte, Inc. recently secured a binding minimum purchase commitment of US$1.475 million for its Symvess acellular tissue engineered vessel in Saudi Arabia, alongside filing a US$20 million follow-on common stock offering and submitting a Marketing Authorization Application for Symvess in Israel for arterial trauma repair. Taken together, these moves highlight Humacyte’s effort to turn its trauma-focused technology into an internationally adopted product, pairing early commercial traction...

Earnings event puts Teekay (TK) under the microscope Teekay (TK) just released full year 2025 results, with sales of US$949.52 million and net income of US$98.11 million, both below the prior year. This has put the stock back in focus for investors. See our latest analysis for Teekay. Teekay’s latest earnings release, which showed lower sales and net income than the prior year, comes after a strong run, with a 90 day share price return of 25.41% and a 1 year total shareholder return of...

Why Zevra Therapeutics Is On Investor Radar Today Zevra Therapeutics (ZVRA) has drawn investor attention after recent trading, with the share price closing at US$9.23 and posting mixed short term returns alongside stronger total returns over the past 3 years. See our latest analysis for Zevra Therapeutics. The recent 7 day share price return of 7.51% and 1 day decline of 1.81% come after a period of steadier momentum. The 30 day share price return of 3.82% and the 3 year total shareholder...

If you are wondering whether Andersen Group at US$27.90 is offering fair value or an opportunity, the next sections will walk through what the current price really reflects. The stock has posted returns of 22.2% over the last 7 days, 24.6% over the last 30 days and 14.4% year to date, which has likely caught the eye of investors watching for changing risk and return profiles. Recent coverage has focused on Andersen Group's share price moves and how investors are reassessing the company, with...

EHang’s earnings jump puts quarterly profit in focus EHang Holdings (NasdaqGM:EH) just released its fourth quarter and full year 2025 results, reporting quarterly sales of CN¥243.78 million and net income of CN¥10.49 million. This follows a net loss in the prior year period. See our latest analysis for EHang Holdings. The earnings surprise has arrived against a weak recent share price backdrop, with a 1 day share price return of 8.46% decline, a 30 day share price return of 19.04% decline,...

BrightSpring Health Services (NasdaqGS:BTSG) is reallocating capital toward acquisitions and organic growth in its core home and clinical services. The company is accelerating de-leveraging efforts to increase financial flexibility. BrightSpring plans to divest its community-living operations, with the transaction expected to close soon. BrightSpring operates in home and clinical care, an area that sits at the intersection of aging demographics, pressure on institutional care settings, and...

JD.com, ticker NasdaqGS:JD, has agreed a new partnership with BYD to build and expand fast charging electric vehicle stations across China. The collaboration combines JD.com's logistics footprint and office network with BYD's electric vehicle expertise to roll out charging sites at scale. The initiative extends JD.com beyond its core e commerce and delivery operations into EV infrastructure and related services. For JD.com, best known for its e commerce platform and nationwide logistics...

Many investors are asking whether Nextpower is still attractively priced after its strong recent run, or whether most of the easier gains may already have been realized. The stock recently closed at US$114.39, with returns of 23.3% year to date and 158.4% over the last year. Over the past week and month, however, it has declined 4.4% and 1.4%, respectively. Recent coverage has focused on how the 1-year return of 158.4% compares with longer term performance of 266.6% over 3 years, providing...

If you are wondering whether CBIZ's share price now reflects its true worth, the starting point is understanding how that price lines up against different measures of value. The stock recently closed at US$27.02, with returns of 3.4% over the last week, a 9.5% decline over the past month, and longer term returns of a 46.8% decline year to date and a 63.0% decline over the past year. These moves sit against a backdrop where investors have been reassessing many professional services names,...

Citizens recently reaffirmed its positive view on Xometry (XMTR) after the company announced a leadership change, with co founder and CEO Randy Altschuler moving to executive chairman and president Sanjeev Singh Sahni set to become CEO. See our latest analysis for Xometry. The leadership transition headlines come after a sharp 37.5% year to date share price decline to US$39.20 and a 32% 30 day share price pullback. However, the 1 year total shareholder return of 52.4% and 3 year total...

XPeng (NYSE:XPEV) closed FY 2025 with fourth quarter revenue of C¥22.3b and basic EPS of C¥0.40, while trailing twelve month figures show total revenue of C¥76.7b and a basic EPS loss of C¥1.20, keeping the story firmly focused on scale over the bottom line. The company’s quarterly revenue moved from C¥10.1b in Q3 2024 to C¥22.3b in Q4 2025, with basic EPS shifting from a C¥1.91 loss to C¥0.40, so the latest results sit against a backdrop of expanding sales and still thin margins that...

Boone Capital Management has disclosed a significant new position in Tyra Biosciences. The investment comes as Tyra Biosciences advances multiple clinical trials centered on FGFR3 biology. The move highlights fresh institutional interest in NasdaqGS:TYRA at a current share price of $37.15. For readers tracking Tyra Biosciences, the company now sits at a share price of $37.15 with substantial recent share price momentum, including a 26.4% return over the past 30 days and 38.7% year to date...

Planet Labs PBC (PL) has just closed out FY 2026 with fourth quarter revenue of US$86.8 million and a basic EPS loss of US$0.48. Trailing twelve month revenue stood at US$307.7 million and EPS at a loss of US$0.80. Over recent periods, the company has seen quarterly revenue move from US$61.6 million in FY 2025 Q4 to US$66.3 million in FY 2026 Q1, US$73.4 million in Q2, US$81.3 million in Q3 and US$86.8 million in Q4. This has come alongside a sequence of widening quarterly EPS losses from...

Intellicheck (IDN) has rounded out FY 2025 with fourth quarter revenue of about US$6.6 million and basic EPS of roughly US$0.08, alongside trailing twelve month revenue of US$22.7 million and EPS of about US$0.07 that reflect a move into positive net income of around US$1.3 million over the year. The company has seen quarterly revenue progress from US$4.9 million in Q1 2025 to US$6.6 million in Q4 2025, with EPS shifting from a small loss of roughly US$0.02 per share early in the year to a...

Linde plans to build a new industrial gases facility in Oshkosh, Wisconsin. The project is intended to expand supply capacity for industrial customers across the Midwest. The development marks a further investment in regional infrastructure for NasdaqGS:LIN. Linde, trading on NasdaqGS:LIN, is moving ahead with construction of a new industrial gases facility in Oshkosh, Wisconsin, adding to its US footprint. The company’s shares most recently closed at $488.15, with a return of 13.8% year to...

If you are wondering whether GPGI is attractively priced or already reflecting a lot of optimism, the current share price at US$17.06 raises some useful questions about what you are really paying for. Recent returns are mixed, with the stock up 3.3% over the last week but showing a 27.4% decline over 30 days, an 8.6% decline year to date, and gains of 51.0% over 1 year, 191.8% over 3 years, and 114.8% over 5 years. These moves sit against a backdrop of ongoing coverage that keeps GPGI on...

FDA grants premarket approval to LivaNova's aura6000 System for adult patients with moderate to severe Obstructive Sleep Apnea who do not benefit from standard therapies. The system uses proximal hypoglossal nerve stimulation and is supported by clinical trial data showing meaningful outcomes, including in harder to treat patient groups. LivaNova (NasdaqGS:LIVN) also discloses work on a next generation, MRI compatible version of the aura6000 with additional features. LivaNova, listed on...

RCI Hospitality Holdings (RICK) FY 2025 earnings at a glance RCI Hospitality Holdings (RICK) has just posted its FY 2025 numbers with Q4 revenue of US$70.9 million and a basic EPS loss of US$0.63, set against trailing 12 month EPS of US$1.23 on revenue of US$279.4 million and earnings growth of 259.1% for the period. Over recent quarters, revenue has moved from US$73.2 million in Q4 2024 to US$71.5 million in Q1 2025, US$65.9 million in Q2, US$71.1 million in Q3 and US$70.9 million in Q4,...

Microvast Holdings (MVST) is back in focus after reaffirming and expanding its long running battery partnership with Iveco Group in Europe, alongside releasing 2025 results, 2026 guidance, and an auditor warning on going concern risks. See our latest analysis for Microvast Holdings. Despite a series of material updates including the expanded Iveco partnership, 2025 results, 2026 guidance and the going concern warning, Microvast’s recent share price performance has been weak. The 30 day share...

If you are wondering whether Viridian Therapeutics at around US$26.98 is offering good value or asking too much, you are in the right place. The stock has recently seen mixed returns, with a 7 day move of 5.9% decline and a 30 day return of 4.0% decline, while still sitting on a 76.8% gain over the past year and 12.1% decline year to date. Recent news coverage has focused on Viridian Therapeutics as a biotech name that continues to attract attention from investors watching the sector. This...

Wondering whether Bob's Discount Furniture is a bargain or a value trap at around US$12.49? This article breaks down what the current price might be implying about the business. The stock has seen sharp recent moves, with a 7 day return of an 18.9% decline and a 30 day return of a 37.2% decline, while the year to date return sits at a 26.6% decline. These swings have put Bob's Discount Furniture back on the radar for investors who are reassessing what they are willing to pay for retailers...